Company

Sirtris, a GSK Company

Source-reviewedGoverned LongevityNext intelligence profile

Evidence reviewed through2026-08-07

Executive intelligence snapshot

Current reviewed view

A reviewed company profile connected to SRT501 and SRT501 multiple-myeloma Phase 2 in the current LongevityNext intelligence graph.

This profile includes 2 reviewed relationship(s) and 2 reviewed source(s).

This view is bounded by reviewed evidence and does not provide a recommendation or a claim beyond the stated review date.

Evidence state

Source-reviewed

Evidence reviewed through2026-08-07

Evidence state

What the evidence supports

Sirtris, a GSK Company

Evidence boundary

Key limitations

Interpretation remains bounded to this reviewed profile and does not support broader inference.
Does not establish efficacy, mechanism falsification, approval, utility, rejuvenation, or investment attractiveness.

Not established

Key unknowns

Program-level outcomes outside this reviewed profile remain unknown; absence is not a negative finding.
The reviewed evidence does not resolve this dimension beyond the recorded boundary.

Next evidence milestone

What would change this view?

No specific evidence milestone is recorded yet.

Evidence reviewed through 2026-08-07.

Intelligence connections

Develops or sponsors

SRT501

Intervention

SRT501 multiple-myeloma Phase 2

Trial

Reviewed source layer

Evidence & sources

These cards show only metadata present in the reviewed source registry.

trial registry

SRT501 Alone or With Bortezomib in Multiple Myeloma

ClinicalTrials.gov

Reference: NCT00920556

Reviewed: 2026-08-06

bibliographic index

A phase 2 study of SRT501 with bortezomib in relapsed or refractory multiple myeloma

PubMed

Reference: 23205612